---
title: "PepGen Inc. Stock 12‑Month Price Target Cut to $10, Implies 495% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286292415.md"
description: "PepGen Inc.'s average stock price target has been reduced from $10.14 to $10, according to 7 analysts, with estimates ranging from $3 to $20 per share. This new target suggests a potential upside of approximately 495% based on the May 12 closing price. The consensus rating remains a 'Buy' with 6 analysts recommending 'Buy', 0 'Hold', and 1 'Sell'."
datetime: "2026-05-13T16:20:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286292415.md)
  - [en](https://longbridge.com/en/news/286292415.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286292415.md)
---

# PepGen Inc. Stock 12‑Month Price Target Cut to $10, Implies 495% Upside

-   According to estimates from 7 analysts, PepGen Inc. stock's average price target has fallen from $10.14 to $10, with forecasts ranging from $3 to $20 per share
-   Based on the May 12 closing price, the updated target implies approximately 495% potential upside
-   Consensus rating remains at “Buy” across 7 covering analysts, with 6 Buys, 0 Holds and 1 Sells

Explore more price target data and ratings for PepGen Inc. on the , and track all previous and future analyst recommendations for PepGen Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [PEPG.US](https://longbridge.com/en/quote/PEPG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)